ClinicalTrialsFinder

Relapsed or Refractory B-cell Malignancies Clinical Trials in Madrid

1 recruitingMadrid, Spain

Showing 1–1 of 1 trials

Recruiting
Phase 1

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

Relapsed or Refractory B-cell Malignancies
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.50 enrolled4 locationsNCT06980116